These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

473 related items for PubMed ID: 12111127

  • 1. 99mTc-MIBI SPET in non-small cell lung cancer in relationship with Pgp and prognosis.
    Yüksel M, Cermik TF, Doğanay L, Karlikaya C, Cakir E, Salan A, Berkarda S.
    Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):876-81. PubMed ID: 12111127
    [Abstract] [Full Text] [Related]

  • 2. Quickly predicting chemotherapy response to paclitaxel-based therapy in non-small cell lung cancer by early technetium-99m methoxyisobutylisonitrile chest single-photon-emission computed tomography.
    Kao CH, Hsieh JF, Tsai SC, Ho YJ, Lee JK.
    Clin Cancer Res; 2000 Mar; 6(3):820-4. PubMed ID: 10741702
    [Abstract] [Full Text] [Related]

  • 3. 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
    Fallahi B, Beiki D, Mousavi SA, Gholamrezanezhad A, Eftekhari M, Fard-Esfahani A, Alimoghaddam K, Mirpour S, Eskandarian A, Saghari M.
    Hell J Nucl Med; 2009 Mar; 12(3):255-9. PubMed ID: 19936339
    [Abstract] [Full Text] [Related]

  • 4. Usefulness of 99mTc-sestamibi scintigraphy in suggesting the therapeutic effect of chemotherapy against gastric cancer.
    Kawata K, Kanai M, Sasada T, Iwata S, Yamamoto N, Takabayashi A.
    Clin Cancer Res; 2004 Jun 01; 10(11):3788-93. PubMed ID: 15173086
    [Abstract] [Full Text] [Related]

  • 5. Tc-99m MIBI SPECT in prediction of prognosis in patients with small cell lung cancer.
    Akgun A, Cok G, Karapolat I, Goksel T, Burak Z.
    Ann Nucl Med; 2006 May 01; 20(4):269-75. PubMed ID: 16856570
    [Abstract] [Full Text] [Related]

  • 6. Usefulness of chest single photon emission computed tomography with technetium-99m methoxyisobutylisonitrile to predict taxol based chemotherapy response in advanced non-small cell lung cancer.
    Shih CM, Hsu WH, Huang WT, Wang JJ, Ho ST, Kao A.
    Cancer Lett; 2003 Sep 10; 199(1):99-105. PubMed ID: 12963129
    [Abstract] [Full Text] [Related]

  • 7. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
    Ak I, Gülbaş Z, Ocak S, Kaya E, Alataş F, Vardareli E, Metintaş M.
    J Comput Assist Tomogr; 2007 Sep 10; 31(5):795-9. PubMed ID: 17895794
    [Abstract] [Full Text] [Related]

  • 8. Monitoring the chemotherapeutic response in primary lung cancer using 99mTc-MIBI SPET.
    Yüksel M, Cermik TF, Karlikaya C, Salan A, Cakir E, Gültekin A, Berkarda S.
    Eur J Nucl Med; 2001 Jul 10; 28(7):799-806. PubMed ID: 11504075
    [Abstract] [Full Text] [Related]

  • 9. [Correlation analysis among expression of ERCC-1, metallothionein, p53 and platinum resistance and prognosis in advanced non-small cell lung cancer].
    Huang PY, Liang XM, Lin SX, Luo RZ, Hou JH, Zhang L.
    Ai Zheng; 2004 Jul 10; 23(7):845-50. PubMed ID: 15248926
    [Abstract] [Full Text] [Related]

  • 10. Technetium-99m methoxyisobutylisonitrile chest imaging for small-cell lung cancer. Relationship to chemotherapy response (six courses of combination of cisplatin and etoposide) and p-glycoprotein or multidrug resistance related protein expression.
    Kao A, Shiun SC, Hsu NY, Sun SS, Lee CC, Lin CC.
    Ann Oncol; 2001 Nov 10; 12(11):1561-6. PubMed ID: 11822755
    [Abstract] [Full Text] [Related]

  • 11. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression.
    Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F, Basdemir G.
    J Nucl Med; 2003 Sep 10; 44(9):1394-401. PubMed ID: 12960182
    [Abstract] [Full Text] [Related]

  • 12. Using technetium-99m methoxyisobutylisonitrile lung single-photon-emission computed tomography to predict response to chemotherapy and compare with P-glycoprotein expression in patients with untreated small cell lung cancer.
    Changlai SP, Tsai CS, Ding HJ, Huang WT, Kao A, Hsu WH.
    Med Oncol; 2003 Sep 10; 20(3):247-53. PubMed ID: 14514974
    [Abstract] [Full Text] [Related]

  • 13. Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer (stage IIIb or IV) with a higher T stage (> T2). Technetium-99m methoxyisobutylisonitrile chest single photon emission computed tomography and P-glycoprotein express ion.
    Hsu WH, Yen RF, Kao CH, Shiun SC, Hsu NY, Lin CC, Lee CC.
    Oncology; 2002 Sep 10; 63(2):173-9. PubMed ID: 12239453
    [Abstract] [Full Text] [Related]

  • 14. Vascular endothelial growth factor, p53, Rb, Bcl-2 expression and response to chemotherapy in advanced non-small cell lung cancer.
    Ludovini V, Gregorc V, Pistola L, Mihaylova Z, Floriani I, Darwish S, Stracci F, Tofanetti FR, Ferraldeschi M, Di Carlo L, Ragusa M, Daddi G, Tonato M.
    Lung Cancer; 2004 Oct 10; 46(1):77-85. PubMed ID: 15364135
    [Abstract] [Full Text] [Related]

  • 15. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
    Azuma K, Sasada T, Kawahara A, Takamori S, Hattori S, Ikeda J, Itoh K, Yamada A, Kage M, Kuwano M, Aizawa H.
    Lung Cancer; 2009 Jun 10; 64(3):326-33. PubMed ID: 18977553
    [Abstract] [Full Text] [Related]

  • 16. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
    Radosavljevic D, Golubicic I, Gavrilovic D, Kezic I, Jelic S.
    J BUON; 2009 Jun 10; 14(2):203-9. PubMed ID: 19650167
    [Abstract] [Full Text] [Related]

  • 17. Monitoring the chemotherapeutic response in primary lung cancer using (99m)Tc-MIBI SPET.
    Yüksel M, Cermik FT, Karlikaya C, Salan A, Cakir E, Gültekin A, Berkarda S.
    Eur J Nucl Med; 2001 Jul 10; 28(7):799-806. PubMed ID: 24770458
    [Abstract] [Full Text] [Related]

  • 18. Clinicopathologic and radiopharmacokinetic factors affecting gamma probe-guided parathyroidectomy.
    Ugur O, Bozkurt MF, Hamaloglu E, Sokmensuer C, Etikan I, Ugur Y, Sayek I, Gulec SA.
    Arch Surg; 2004 Nov 10; 139(11):1175-9. PubMed ID: 15545562
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of different markers in non-small cell lung cancer: prognostic value of clinical staging, tumour cell detection and tumour marker analysis for tumour progression and overall survival.
    Kasimir-Bauer S, Schleucher N, Weber R, Neumann R, Seeber S.
    Oncol Rep; 2003 Nov 10; 10(2):475-82. PubMed ID: 12579292
    [Abstract] [Full Text] [Related]

  • 20. Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer.
    De Petris L, Orre LM, Kanter L, Pernemalm M, Koyi H, Lewensohn R, Lehtiö J.
    Lung Cancer; 2009 Mar 10; 63(3):410-7. PubMed ID: 18620780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.